Program DHC-Virtual
20 - 21 January 2021
Clinical Abstracts session 1
Effective treatment with Ibrutinib in cold agglutinin disease/cold agglutinin syndrome
20 January
08:42 08:54
M. Jalink

Effective Treatment of cold agglutinin disease/cold agglutinin syndrome with Ibrutinib: an international case series 

Marit Jalink (1,2), Sigbjørn Berentsen (3), Jorge J. Castillo (4), Steven Treon (4), Bruno Fattizzo (5), Ramona Cassin (5), Masja de Haas (2,6,7), Andrea Patriarca (8), Shirley D'Sa (9), Josephine M.I. Vos (1,10)
(1) Amsterdam UMC, University of Amsterdam, Department of hematology, Amsterdam, (2) Sanquin, Center for Clinical Transfusion Research, Amsterdam, (3) Haugesund Hospital, Department of Research and Innovation, Norway, (4) Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, (5) Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico and University of Milan, UOC Ematologia, Milan, (6) Department of Hematology, Leiden University Medical Center, Leiden, (7) Sanquin, Department of Immunohematology Diagnostics, Amsterdam, (8) Università del Piemonte Orientale, Division of Hematology, Department of Translational Medicine, Novara, (9) University College London Hospitals NHS Foundation Trust, UCLH Centre for Waldenström’s Macroglobulinemia and Related Conditions, London, (10) Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam
No potential conflicts of interest

In cold agglutinin mediated autoimmune hemolytic anemia (cAIHA), anti-red blood cell

autoantibodies lead to complement-mediated hemolysis with or without symptoms of acrocyanosis after exposure at low temperatures. For patients with significant hemolytic anemia or acrocyanosis despite thermal protection, rituximab is the most accepted first line treatment with an overall response rate of 50% and median duration of response <1 year. Cytotoxic combinations such as rituximab-bendamustine produce more sustained remissions, although with concerns for long-term adverse effects and stem cell toxicity. Studies involving complement inhibitors are showing promising results on hemolysis, although cold induced peripheral symptoms will not improve. Recent international guidelines on cAIHA suggest treatment with the Bruton tyrosine kinase (BTK)-inhibitor ibrutinib in refractory patients with cAIHA. We evaluated the efficacy of ibrutinib on anemia, hemolysis and acrocyanosis in patients with cold agglutinin-mediated AIHA (CAD/CAS).


An international retrospective study was undertaken of cAIHA patients (CAD/CAS) treated with BTK inhibition using a preformed questionnaire. For eligible patients, laboratory and clinical data regarding underlying disease, bone marrow pathology, hemolytic parameters and patient-reported acrocyanosis were collected at diagnosis, 30 days, 3 months, 6 months and 12 months and last date of follow up. Hemoglobin (Hb) response was considered none (NR), partial (PR, >2 g/dL Hb increase or >10g/dL) or complete (CR, >12g/dL). Adverse events were graded according to the Common Terminology Criteria, version-5.0 (2017).


So far, 10 patients with cAIHA treated with a BTK-inhibitor (all involving ibrutinib) could be included in the study. Patients were followed from April 2014 until June 2020 at 5 centers (Italy (2), Norway, The United Kingdom and The United States). Median duration of follow up was 20 months (1-74 months). The indication to start treatment was cAIHA based in all but 1 case (CLL). Median previous number of therapies was 2. All patients had a complement-mediated hemolytic anemia, 7 were transfusion-dependent, and 7 reported symptoms of acrocyanosis at the initiation of ibrutinib. After initiation of ibrutinib, all patients showed an improvement in hemoglobin (median rise: 4.4 g/dL) resulting in 1 PR and 9 CR. All 7 transfusion-dependent patients became transfusion independent (5 within 30 days). In all but 1 patient, markers of hemolysis (LDH, bilirubin) improved after initiation of ibrutinib. All 7 patients with acrocyanosis reported clear clinical improvement, with complete resolution of symptoms in 5. There was 1 adverse event (grade 1 bleeding). Data collection is still ongoing and future updates are expected.


Data show that ibrutinib is effective in the treatment of cAIHA with a notable and brisk improvement of both the hemolytic anemia as well as the cold induced peripheral symptoms.